Ranbaxy Receives US Approval for Manufacturing and Marketing Ramipiril

by Gopalan on  March 9, 2009 at 8:47 PM Corporate News   - G J E 4
 Ranbaxy Receives US Approval for Manufacturing and Marketing Ramipiril
India's Ranbaxy Laboratories has received the nod of U.S. Food and Drug Administration to manufacture and market ramipril capsules.

Ramipril is used in the treatment of cardiovalscular diseases.

Ramipril is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the work load of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys resulting in a stroke, heart failure, or kidney failure. Hypertension may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.

Ramipril works by blocking an enzyme in the body that is necessary to produce a substance that causes blood vessels to tighten. As a result, the blood vessels relax. This lowers blood pressure and increases the supply of blood and oxygen to the heart.

Ramipril is also used in some patients after a heart attack. After a heart attack, some of the heart muscle is damaged and weakened. The heart muscle may continue to weaken as time goes by. This makes it more difficult for the heart to pump blood. Ramipril may be started within the first few days after a heart attack to increase survival rate.

In addition, ramipril is used to lessen the chance of heart attacks, strokes, or death in people who are 55 years of age or older and have serious heart disease.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like